Kolexia
Eclache-Saudreau Virginie
Pharmacien
Hôpital Avicenne
Bobigny, France
96 Activités
6 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Syndromes myélodysplasiques Leucémie chronique lymphocytaire à cellules B Leucémie lymphoïde Aberrations des chromosomes Leucémie myéloïde Leucémie aigüe myéloïde Délétion de segment de chromosome Trisomie

Industries

Pfizer
1 collaboration(s)
Dernière en 2021
{{person.topindus2.name}}
{{person.topindus2.tot}} collaboration(s)
Dernière en {{person.topindus2.last}}
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Retrospective analysis of a cohort of 41 B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study).
Haematologica   01 juin 2023
The presence of a chromosomal abnormality in cytopenia without dysplasia identifies a category of high-risk clonal cytopenia of unknown significance.
Genes, chromosomes & cancer   30 novembre 2022
The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH).
Leukemia   16 avril 2022
The CADM1 tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11.
Blood advances   05 avril 2022
TP53 mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia.
American journal of hematology   01 février 2022
Characterisation of a New Clinical Presentation of Chronic Lymphocytic Leukemia with Symptomatic Nasopharyngeal Mucosa Involvement
Blood   23 novembre 2021
Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization (FILO).
American journal of hematology   01 juillet 2021
Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 rearrangement
Blood   05 novembre 2020
Prevalence, distribution and predictive value of XPO1 mutation in a real-life chronic lymphocytic leukaemia cohort.
British journal of haematology   13 août 2020
SPIRIT: A Phase III Prospective Randomized Comparison of Imatinib at a Dose of 400mg in Combination With Peg-Interferon-alpha2a (Peg-IFNa2a) or Cytarabine (Ara-C)Versus Imatinib at a Dose of 600mg Versus Imatinib a Dose of 400mg for Previously Untreated Chronic Myelogenous Leukemia (CML) in Chronic Phase
Essai Clinique (Novartis)   10 avril 2020